Dyne Therapeutics (DYN) said Tuesday that the US Food and Drug Administration granted fast-track designation for its experimental therapy, DYNE-101, to treat a genetic neuromuscular disease, myotonic dystrophy type 1.
DYNE-101 is currently being evaluated in the ongoing phase 1/2 trial.
The company said it plans to submit for US accelerated approval in the first half of next year.
Shares of the company were up more than 4% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.